EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Evaluation of clinical outcomes of raised intraocular pressure following intravitreal triamcinolone acetonide injection

Pragya Singh, R Krishnaprasad, Guruprasad Ayachit, Shrinivas Joshi

Romanian Journal of Ophthalmology · 2024

DOI: 10.22336/rjo.2024.08 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Romanian Journal of Ophthalmology, 2024. Verfasst von Pragya Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: MM Joshi Eye Institute, Karnataka, India. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Glaucoma, Glaucoma, Open-Angle, Macular Degeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the incidence, risk factors, and treatment outcomes in intravitreal triamcinolone acetonide injection (IVTA) induced intraocular pressure rise and to compare IOP rise in 1-mg and 2-mg IVTA. Materials and methods: Prospective observational study conducted in all eyes receiving IVTA. Any pre-existing glaucoma and patients who received IVTA or dexamethasone implant in the last 6 months were excluded.

Results

9 between 61-70 years of age developed an IOP spike. The mean and standard deviation of age in years was 61.95 ± 8.70. Maximum eyes had ME due to Diabetic Retinopathy (53.3%). All cases of uveitic ME were reported to have an IOP spike. 2 out of 3 high myopic eyes and 1 eye with thyroid abnormality had an IOP spike. High IOP was found in 13 eyes, with more than 25 mm Hg rise in 4 eyes and more than 5 mm Hg rise from baseline IOP in 9 eyes. The mean and standard deviation of time taken for IOP raise (in days) was 46.39 ± 37.68. A total of 38 eyes received 1 mg of IVTA and the rest 22 received 2 mg of IVTA. 23.7% of 1 mg eyes experienced an IOP rise while it was 18.2% in eyes with 2 mg IVTA. The injection was repeated in 12 eyes and 41.7% developed an IOP spike among them. The independent "t" test results showed that there was a significant difference in the mean of IOP (Pre-injection) concerning the IOP rise (P=0.007*). 1 eye had IVTA crystals in the anterior chamber with raised IOP of 30 mm Hg. 1 out of 13 eyes with raised IOP needed 2 AGMs, the other 12 eyes responded well to 1 AGM.

Discussion

IVTA is widely used in refractory cases of ME and steroid-induced glaucoma is the most common side effect of IVTA. To the best of our knowledge, there is a lack of literature on prospective studies on IVTA-associated risk factors, patterns of IOP elevation, and treatment outcomes. The pre-injection mean ± SD baseline IOP for uneventful eyes was 12.87±2.65 and the pre-injection mean IOP for eyes with IOP event was 15.23±2.89 (P=0.007*).

Conclusion

We proposed that TA is an independent risk factor for post-intravitreal injection IOP spike. IVTA causes a maximum IOP spike at 1 to 2 months and has a protracted course that responds to anti-glaucoma medications. High baseline IOP, a repeated dose of IVTA, the presence of TA crystals in the anterior chamber, and high myopia were associated with significant IOP elevation. Abbreviations: ACD = Anterior chamber depth, AS = Anterior segment, AGM = Anti-glaucoma medications, ARMD = Age-related macular degeneration, BCVA = Best-corrected visual acuity, BRVO = Branch retinal vein occlusion, CCT = Central corneal thickness, CRVO = Central retinal vein occlusion, CME = Cystoid macular edema, CNVM = Choroidal neovascularization membrane, CSME = Clinically significant macular edema, DR = Diabetic retinopathy, ERM = Epiretinal membrane, IOP = Intraocular pressure, IGS = Irvine-Grass syndrome, GAGs = Glycosaminoglycans, IVTA = Intravitreal triamcinolone acetonide injection, ME = Macular edema, NVG = Neovascular glaucoma, OHT = Ocular hypertension, PDS = Pigment dispersion syndrome, PACG = Primary closed angle glaucoma, POAG = Primary open-angle glaucoma, PXF = Pseudoexfoliation, VA = Visual acuity, VEGF = Vascular endothelial growth factors, VH = Vonherick's grading, SD = Standard deviation, TA = Triamcinolone acetonide, TIGR = Trabecular meshwork inducible glucocorticoid response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyGlaucomaGlaucoma, Open-AngleMacular DegenerationMacular EdemaMyopiaRetinal Vein OcclusionHumansAntiglaucoma AgentsIntraocular PressureProspective StudiesTriamcinolone AcetonideMiddle AgedAged

Stichwörter der Autor:innen

anti-glaucoma medicationsintraocular pressureintravitreal triamcinolone acetonide injectionsteroid-induced glaucoma

Substanzen

Antiglaucoma AgentsTriamcinolone Acetonide

Autor:innen und Institutionen

  • MM Joshi Eye Institute, Karnataka, India.
  • Department of Glaucoma, MM Joshi Eye Institute, Karnataka, India.
  • Department of Vitreoretina services, MM Joshi Eye Institute, Karnataka, India.

Zitieren

APA

Singh, P., Krishnaprasad, R., Ayachit, G., & Joshi, S. (2024). Evaluation of clinical outcomes of raised intraocular pressure following intravitreal triamcinolone acetonide injection. Romanian Journal of Ophthalmology. https://doi.org/10.22336/rjo.2024.08

Vancouver

Singh P, Krishnaprasad R, Ayachit G, Joshi S. Evaluation of clinical outcomes of raised intraocular pressure following intravitreal triamcinolone acetonide injection. Romanian Journal of Ophthalmology. 2024. doi:10.22336/rjo.2024.08

BibTeX
@article{Singh2024,
  author = {Singh, Pragya and Krishnaprasad, R and Ayachit, Guruprasad and Joshi, Shrinivas},
  title = {Evaluation of clinical outcomes of raised intraocular pressure following intravitreal triamcinolone acetonide injection},
  journal = {Romanian Journal of Ophthalmology},
  year = {2024},
  doi = {10.22336/rjo.2024.08}
}
Kostenlos starten →